China Medical Device CRO & NMPA Clinical Trial Services
Cisema is a specialized Contract Research Organization (CRO) and regulatory consulting partner, supporting medical device and IVD manufacturers through the entire China clinical trial and product registration process. From study design, protocol development, and execution to regulatory submission and final National Medical Product Administration (NMPA) approval, we provide a fully integrated pathway to market success.
China has rapidly transformed from a secondary research market into a global leader in clinical development. In 2024 alone, over 4,900 clinical trials were conducted, reflecting a 13.9% year-over-year increase. With sweeping regulatory reform, increasing global data harmonization, and accelerated clinical trial approvals, China has become a strategic destination for global clinical studies, not only for pharmaceuticals, but critically for medical devices and in vitro diagnostics (IVDs).

Combined Years of Experience
Clinical Trial Sites Used
Mid-Sized Manufacturer Clients
Medical Device Certificates as NMPA Legal Agent
Cisema’s Clinical Trial Services for Medical Devices & IVDs
Clinical Trial Strategy & Protocol Development
We develop a China clinical trial strategy based on your medical device, risk classification, intended use, and regulatory pathway:
NMPA Regulatory & Ethics Committee (IEC) Submissions
We prepare and coordinate the regulatory and ethicssubmissions required to initiate your medical device clinical trial in China:
Clinical Site Selection & Principal Investigator Engagement
We identify qualified hospitals and investigators based on your medical device, study requirements, and target patient population:
Clinical Trial Execution & Management
We provide local coordination and clinical trial oversight throughout study execution to maintain quality, compliance, and progress:
Clinical Data Management & Statistical Analysis
We manage and analyze clinical trial data to generatereliable, submission-ready evidence:
Trial Close-Out & NMPA Dossier Compilation
We finalize the clinical trial and prepare the documentationrequired for NMPA review and medical device registration:
Market Access & Commercial Strategy
Following product approval, we support your transition to commercialization by guiding pricing, reimbursement, and stakeholder engagement strategies. Our market access experts help you define and communicate your product’s value within the local healthcare landscape.
Post-Market Clinical Support & Real World Evidence
We support post-market evidence generation tomaintain compliance, monitor device performance and safety, and support futureregulatory needs:
Why MedTech Leaders Partner with Cisema for China Medical Device Clinical Trials
As a specialist Contract Research Organization (CRO) and regulatory partner, Cisema guides medical device and IVD manufacturers through every stage of China clinical trials and NMPA registration, from study design to final approval. By aligning clinical and NMPA regulatory requirements from the outset, we streamline the process, eliminates costly handovers, and serve as your single-source partner for a clear, cost-transparent route to the Chinese market.
1
Built for International Sponsors
We understand global quality standards, Western documentation, and multinational decision-making, eliminating the misunderstandings and delays typical of domestic-focused CROs.
2
Flexible, Tailored Delivery
Rather than forcing your study into a standardized CRO model, we keep senior leadership close to delivery and tailor teams and workflows to your medical device and registration goals.
3
Coordinated Trial Execution
We align sponsors, regulatory teams, hospitals, investigators, and service providers from day one, resolving bottlenecks early and keeping key decisions on track.
4
Dual Project Management
We pair a sponsor-facing lead focused on strategy and budgets with a dedicated clinical trial manager driving daily execution in China, bridging headquarters with on-the-ground reality.
Our 5-Step Process for China Medical Device Trial Success
Step 1: Build a Dedicated Project Team
Create a customized Clinical Trial Project Development (CTPD) plan to optimize costs, timelines, and overall project efficiency.
Step 2: Build a Dedicated Project Team
Establish a professional team comprising a Project Supervisor, client-side Project Manager, site Project Manager, CRA, and medical experts.
Step 3: Build a Dedicated Project Team
Hold regular meetings between Cisema’s team and the client’s team to maintain alignment and address project issues promptly.
Step 4: Conduct a Protocol Discussion Panel
Organize a Protocol Discussion Panel involving the Principal Investigator (PI) and client to review and align on the clinical trial protocol.
Step 5: Support the NMPA Review Process
Manage clinical data collection and report preparation while supporting the client throughout the NMPA technical review and supplementary process.
China Medical Device CRO FAQs
Not necessarily. Devices on the NMPA Exemption Catalogue or supported by sufficient existing clinical evaluation may bypass local clinical trials. Cisema can assess your product and evidence to identify the leanest pathway.
Yes, provided it meets NMPA’s overseas clinical data acceptance guidelines. We evaluate your global dataset for ethnic differences and GCP compliance to determine if supplemental local data is needed.
CROs with an on the ground presence in China and global perspective provide the regulatory knowledge, hospital and investigator network, and on-the-ground coordination needed to manage China-specific clinical trial requirements. Cisema combines these capabilities with international regulatory expertise.
Yes. We match your medical device with suitable hospitals and investigators based on your study requirements, and target patient population. We can also coordinate site start-up, contracting, training, and ongoing communication throughout the clinical trial.
Timelines vary based on enrollment targets, site count, and ethics board approvals. Cisema can assess your project and identify key milestones, dependencies, and potential timeline risks before the study begins.
Pricing depends on trial scope, site volume, patient cohort size, and data management needs. We provide transparent, itemized proposals tailored to your project milestones.
Why Global Sponsors Choose China for Medical Device & IVD Clinical Trials
Unprecedented Scale and Opportunity
- 4,900+ clinical trials conducted in 2024, including pharmaceutical trials
- 51.8% of trials focused on innovative products
- Large, treatment-naive patient populations
- Growth in multinational and global clinical trials
- Extensive hospital network, including Class III Grade A hospitals in major cities, providing a competitive landscape for clinical research
Regulatory Transformation Under the NMPA
- 60-working-day silent approval mechanism for clinical trial applications
- Proposed 30-day review timeline for priority products
- Shift from site accreditation to site registration
- Greater alignment with ICH standards for global data acceptance
Cost and Speed Advantages
- Lower costs compared with many other markets
- Expanding CRO ecosystem providing full-service support
- Backed by the Chinese government through policies promoting Innovation, quality control and new guidance to streamline the clinical trial process.
Discuss Your China Medical Device Clinical Trial
Cisema’s clinical trial and regulatory specialists are ready to guide your medical device or IVD through every step in China. Let us help you design, execute, and submit a successful clinical trial that meets NMPA requirements, ensures data accuracy, and accelerates your product’s market entry.









